
FDA Clears Teva’s Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Summary
Teva Pharmaceutical Industries has received FDA approval for its sublingual film, IGALMI, enabling at-home treatment for acute agitation related to specific mental health conditions. This regulatory decision marks a first-of-its-kind authorization allowing adult patients to manage these episodes independently outside of a medical facility.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use. This regulatory decision makes IGALMI the first FDA-approved treatment that adults can use at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. IGALMI (dexmedetomidine) sublingual film is a prescription…
Source: Read the full story at Top Stories Feed